#POLB Poolbeg Pharma – Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick

17 January, 2022- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick. Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, […]

#POLB Poolbeg Pharma – Poolbeg to develop oral vaccine delivery platform

16 December, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed a binding term sheet, encompassing all commercial terms, with AnaBio Technologies (AnaBio), with a full licence and collaboration agreement to follow. The partnership allows Poolbeg exclusive access to AnaBio’s microencapsulation and nanoencapsulation […]

Poolbeg Pharma #POLB – Drug Discovery

  Artificial Intelligence can play an exciting role in Infectious Disease drug discovery. Learn more about how #AI can deliver transformational data analysis in our recent article in @Pharmafocus , written by Liam Tremble, PhD Project Manager, R&D Operations https://bit.ly/31UZFbz

Poolbeg Pharma #POLB – agrees option agreement with UCD

polb irish times

#POLB featured in the Irish Times following the recently announced Option Agreement to licence #MelioVac with University College Dublin Potential to generate significant returns for investors Contributing to the global response to the threat of infectious diseases https://www.irishtimes.com/business/health-pharma/poolbeg-pharma-agrees-option-agreement-with-ucd-1.4747770

#POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate

6 December 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor Siobhán McClean , through NovaUCD, the university’s knowledge transfer office.   The Company […]

#POLB Poolbeg Pharma – Scientific Advisory Board Appointment

25 November, 2021- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has appointed Professor Daniel Hoft to its Scientific Advisory Board . Prof Hoft, M.D., Ph.D. is the Dianna and J. Joseph Adorjan Endowed Chair of Infectious Diseases and Immunology, and Director of the Division […]

#POLB Poolbeg Pharma – Update on POLB 001 Clinical Development

18 November 2021 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza. The Company intends to […]